trier's

trier's disease in one patient.

By | December 7, 2000

A drug therapy seems to have been effective in reversing the symptoms of Ménétrier's disease in a man from Texas, a report in the 7 December New England Journal of Medicine reveals.

Ménétrier's disease is quite rare and causes a thickening of the stomach lining, and a complete absence of parietal cells, which produce stomach acid. This results in symptoms of persistent vomiting and swelling in the legs. Robert Coffey and colleagues from Vanderbilt-Ingram Cancer Center, Texas, have been researching the role of the epidermal growth factor (EGF) receptor and one of the factors that binds to it — transforming growth factor-α (TGFα) — in the stomach. They have found that the EGF receptor is involved in the growth of cells in the stomach characteristic of this premalignant stomach disorder. Enhanced EGF signalling seems to cause excessive amounts of TGFα in Ménétrier's patients.

The authors treated a 48-year-old man with a new drug, a monoclonal antibody that blocks activation of the EGF receptor, called C225. The effect of the drug was quick and impressive. Dr Coffey commented: "By the day after his first injection, he was already feeling better." His vomiting virtually ceased, and gastric biopsies taken the day before and after revealed a marked reduction in proliferation of surface mucous cells and an increase in levels of gastrin, which prompts development of acid-producing parietal cells.

Dr Coffey concludes: "It seems clear that Ménétrier's disease results because of enhanced signalling of the EGF receptor. We think it's TGFα, but other ligands for the EGF receptor may also have this effect. We'll now be able to go back to the mouse model and address these issues."

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham